After the release of encouraging topline safety results from the Phase 1 SB101 clinical study of SON-1010, shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN)
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) has seen a significant boost in share price, with the stock rising to $6.11, or a 20.28% increase. The
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.